Overview

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor
Phase:
Phase 2
Details
Lead Sponsor:
Italian Sarcoma Group
Treatments:
Dacarbazine
Doxorubicin
Liposomal doxorubicin
Trabectedin